Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innova CaptabBOM:544067 -1.27%67 Operating Margin % is 13.04% as of Jun. 2026, which is 10% above its 10-year median of 11.84. GuruFocus rates BOM:544067 with a GF Score™ of 67/100 and a GF Value™ of ₹1,059.45 (Fairly Valued). The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Innova Captab ranks better than 61.17% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Innova Captab's Operating Income for the
three
months ended in Jun. 2026 was ₹614 Mil. Innova Captab's Revenue for the
three
months ended in Jun. 2026 was ₹4,709 Mil. Therefore, Innova Captab's Operating Margin % for the quarter that ended in Jun. 2026 was 13.04%.
Good Sign:
Innova Captab Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Innova Captab's Operating Margin % or its related term are showing as below:
BOM:544067'
s Operating Margin % Range Over the Past 10 Years
Min: 10.94 Med: 11.84 Max: 13.4
Current: 12.21
BOM:544067's Operating Margin % is ranked better than 61.17% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7.21
vs BOM:544067: 12.21
Innova Captab's 5-Year Average Operating Margin % Growth Rate was 1.70% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Innova Captab Operating Margin % Related Terms
Innova Captab Operating Margin % Historical Data
* Premium members only.
The historical data trend for Innova Captab's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Innova Captab's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Innova Captab's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innova Captab (BOM:544067) has a Operating Margin % of 13.04% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Innova Captab and its competitors. This is 10% above median its historical median of 11.84. Over the past decade, Innova Captab's Operating Margin % has ranged from 10.94 to 13.40. According to the industry distribution chart, Innova Captab ranks #372 out of 958 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is Innova Captab's Operating Margin % too high?
Innova Captab's current Operating Margin % of 13.04% is 10% above median its 10-year median of 11.84. Over the past 10 years, this metric has ranged from a low of 10.94 to a high of 13.40. The Drug Manufacturers industry median Operating Margin % is 7.21. Innova Captab's value of 13.04% is 80.9% above this industry median. Based on the distribution chart, Innova Captab ranks #372 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Innova Captab has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #372 out of 958 companies for Operating Margin %. This puts Innova Captab in the upper half of its industry. The industry median Operating Margin % is 7.21. Innova Captab's value of 13.04% is 80.9% above this benchmark. Historically, Innova Captab's own Operating Margin % has ranged from 10.94 to 13.40 over the past decade. While the company's 10-year median is 11.84 vs. the industry median of 7.21, Innova Captab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.21, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current Operating Margin % of 13.04% is 80.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current Operating Margin % is 13.04%, which is 10% above median its own 10-year median of 11.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Based on GuruFocus' analysis, Innova Captab (BOM:544067) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,059.45, compared to a current price of ₹1,035.10 — trading 2.3% below its estimated fair value. The current Operating Margin % is 13.04%, which is 10% above median its 10-year median of 11.84 and 80.9% above the Drug Manufacturers industry median of 7.21. Innova Captab's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Innova Captab (BOM:544067), the current Operating Margin % is 13.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innova Captab (BOM:544067) Overvalued in 2026?
Based on GuruFocus' analysis, Innova Captab stock appears to be undervalued.
The current stock price of ₹1,035.10 is trading 2.3% below its estimated GF Value™ of ₹1,059.45.
GuruFocus considers Innova Captab to be Fairly Valued.
Key valuation signals for BOM:544067:
Operating Margin %: 13.04% (10% above median its 10-year median of 11.84)
GF Value™: ₹1,059.45 vs. price of ₹1,035.10 (2.3% below fair value)
Industry Position: 80.9% above the Drug Manufacturers median (#372 of 958)
No single metric tells the full story. See the BOM:544067 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
67GF Score
Get the complete analysis for BOM:544067
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544067 has been successfully added to your 
